Barriers and facilitators to implementing polypharmacy management frameworks: a theory based qualitative exploration of key stakeholders.

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
S Al Bulushi, T McIntosh, H Talkhan, A Grant, D Stewart, M Al Famy, S Cunningham
{"title":"Barriers and facilitators to implementing polypharmacy management frameworks: a theory based qualitative exploration of key stakeholders.","authors":"S Al Bulushi, T McIntosh, H Talkhan, A Grant, D Stewart, M Al Famy, S Cunningham","doi":"10.1007/s11096-024-01844-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inappropriate polypharmacy arises through many factors including deficiencies in prescribing processes. Most research has focused on solutions at the clinician/patient levels with less at the organisational level.</p><p><strong>Aim: </strong>To explore key stakeholder identified barriers and facilitators to implementation of an organisational level polypharmacy management framework.</p><p><strong>Method: </strong>Qualitative data were collected within the Ministry of Health in Oman. Key stakeholders were purposively sampled encompassing senior representatives of pharmacy, medicine, and nursing directors; healthcare policymakers; patient safety leaders; and academic leaders. A semi-structured interview schedule was developed informed by a recent scoping review and underpinned by the Consolidated Framework for Implementation Research (CFIR). Interviews, which continued until data saturation, were audio-recorded, transcribed and analysed using the Framework Approach.</p><p><strong>Results: </strong>Thirteen key stakeholders were interviewed, with representation of each target group. Facilitators largely mapped to the CFIR domain of inner setting (i.e., aspects of stakeholder awareness, the electronic health system and national leadership), intervention characteristic (evidence gaps), characteristics of individuals (stakeholders and champions) and process (change strategy). Barriers also largely mapped to the inner setting (policy absence, communication and health professional practice) and outer setting (resource needs).</p><p><strong>Conclusion: </strong>This study has illuminated the facilitators and barriers to the implementation of an organisational level polypharmacy management framework. Further work is required to translate these themes into an actionable plan to implement the framework. Particular attention is required for aspects of the CFIR domain of inner setting (i.e., the internal context within which implementation occurs) as most barriers mapped to this domain.</p>","PeriodicalId":13828,"journal":{"name":"International Journal of Clinical Pharmacy","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11096-024-01844-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Inappropriate polypharmacy arises through many factors including deficiencies in prescribing processes. Most research has focused on solutions at the clinician/patient levels with less at the organisational level.

Aim: To explore key stakeholder identified barriers and facilitators to implementation of an organisational level polypharmacy management framework.

Method: Qualitative data were collected within the Ministry of Health in Oman. Key stakeholders were purposively sampled encompassing senior representatives of pharmacy, medicine, and nursing directors; healthcare policymakers; patient safety leaders; and academic leaders. A semi-structured interview schedule was developed informed by a recent scoping review and underpinned by the Consolidated Framework for Implementation Research (CFIR). Interviews, which continued until data saturation, were audio-recorded, transcribed and analysed using the Framework Approach.

Results: Thirteen key stakeholders were interviewed, with representation of each target group. Facilitators largely mapped to the CFIR domain of inner setting (i.e., aspects of stakeholder awareness, the electronic health system and national leadership), intervention characteristic (evidence gaps), characteristics of individuals (stakeholders and champions) and process (change strategy). Barriers also largely mapped to the inner setting (policy absence, communication and health professional practice) and outer setting (resource needs).

Conclusion: This study has illuminated the facilitators and barriers to the implementation of an organisational level polypharmacy management framework. Further work is required to translate these themes into an actionable plan to implement the framework. Particular attention is required for aspects of the CFIR domain of inner setting (i.e., the internal context within which implementation occurs) as most barriers mapped to this domain.

实施多药管理框架的障碍和促进因素:基于关键利益相关者的理论定性探索。
背景:不当的多药是由多种因素引起的,包括处方过程中的缺陷。大多数研究都集中在临床医生/患者层面的解决方案上,而组织层面的解决方案较少。目的:探索关键利益相关者确定的障碍和促进实施组织层面的综合药房管理框架。方法:在阿曼卫生部收集定性资料。有目的地对主要利益相关者进行抽样,包括药房、医学和护理主管的高级代表;医疗保健政策制定者;患者安全负责人;还有学术领袖。根据最近的范围审查,制定了半结构化访谈时间表,并以实施研究综合框架(CFIR)为基础。访谈一直持续到数据饱和,使用框架方法进行录音、转录和分析。结果:采访了13个关键利益相关者,每个目标群体都有代表。促进因素主要映射到内部环境(即利益相关者意识、电子卫生系统和国家领导等方面)、干预特征(证据差距)、个人特征(利益相关者和拥护者)和过程(变革战略)的CFIR领域。障碍也主要与内部环境(政策缺失、沟通和卫生专业实践)和外部环境(资源需求)有关。结论:本研究阐明了组织层面多药管理框架实施的促进因素和障碍。需要进一步开展工作,将这些主题转化为实施该框架的可操作计划。需要特别注意内部设置的CFIR领域的各个方面(即,发生实现的内部上下文),因为大多数障碍都映射到该领域。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.10
自引率
8.30%
发文量
131
审稿时长
4-8 weeks
期刊介绍: The International Journal of Clinical Pharmacy (IJCP) offers a platform for articles on research in Clinical Pharmacy, Pharmaceutical Care and related practice-oriented subjects in the pharmaceutical sciences. IJCP is a bi-monthly, international, peer-reviewed journal that publishes original research data, new ideas and discussions on pharmacotherapy and outcome research, clinical pharmacy, pharmacoepidemiology, pharmacoeconomics, the clinical use of medicines, medical devices and laboratory tests, information on medicines and medical devices information, pharmacy services research, medication management, other clinical aspects of pharmacy. IJCP publishes original Research articles, Review articles , Short research reports, Commentaries, book reviews, and Letters to the Editor. International Journal of Clinical Pharmacy is affiliated with the European Society of Clinical Pharmacy (ESCP). ESCP promotes practice and research in Clinical Pharmacy, especially in Europe. The general aim of the society is to advance education, practice and research in Clinical Pharmacy . Until 2010 the journal was called Pharmacy World & Science.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信